Investors & media

Pure Biologics is a Polish biopharmaceutical company operating in the area of modern biological drugs. On the market since 2010, it was first in Poland to focus on developing new and innovative therapeutic molecules, not simply generic or biosimilar, based on antibodies and aptamers to be used in immuno-oncology and rare diseases applications.

In 2018, Pure Biologics entered the NewConnect market , and in 2020 transferred to the Main Market of the Warsaw Stock Exchange (as PURE).

Our team combines the recruitment of talent from renowned research groups, know-how acquired from years of activity, and an effective operating model, to drive the evolution of our own internal research projects, belonging to the most promising sectors of pharmaceutics.

Sources of funding for our therapeutic portfolio include grants from the European Union, complemented with revenue from contracted research delivered for pharmaceutical and biotechnology companies, as well as the capital invested by our company shareholders. The long-term strategy includes the partial reinvestment of profits from commercialization of our portfolio into our R&D activities and further development of the research program.

Shareholders

13,41%
302298 shares
TFI Allianz Polska S.A.
11,44%
257817 shares
Filip Jeleń
(Chairman of the Board)
7,10%
160104 shares
Maciej Mazurek
6,80%
153220 shares
Augebit FIZ
6,50%
146576 shares
Piotr Jakimowicz
54,75%
1233985 shares
Other shareholders
13,41%
302298 votes
TFI Allianz Polska S.A.
11,44%
257817 votes
Filip Jeleń
(Chairman of the Board)
7,10%
160104 votes
Maciej Mazurek
6,80%
153220 votes
Augebit FIZ
6,50%
146576 votes
Piotr Jakimowicz
54,75%
1233985 votes
Other shareholders
Share and votes table
Shareholder % shares % votes
TFI Allianz Polska S.A. 13,41 13,41
Filip Jeleń 11,44% 11,44%
Maciej Mazurek 7,10% 7,10%
Augebit FIZ 6,80% 6,80%
Piotr Jakimowicz 6,50% 6,50%
Other shareholders 54,75 54,75

Calendar of events and reports

1 III
2022
Beginning of closed period before the announcement of annual financial report
31 III
2022
2021 annual financial report
16 IV
2022
Beginning of closed period before the announcement of quarterly financial report
16 V
2022
Q1 2022 periodic financial report
23 VI
2022
Ordinary General Meeting
17 VIII
2022
Beginning of closed period before the announcement of half-yearly financial report
16 IX
2022
HY1 2022 periodic financial report
Today
16 X
2022
Beginning of closed period before the announcement of quarterly financial report
15 XI
2022
Q3 2022 periodic financial report

Download

Memoranda and prospectuses (PL)

Documents prepared in connection with the application for the introduction of financial instruments to trading conducted by the Warsaw Stock Exchange S.A.

Contact for investors

Martyna Koj

Director of the Company Office
Investor Relations Representative

Address for submitting notifications

According to Art. 19 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR)

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers